Thiogenesis Therapeutics, Corp. News Releases

Thiogenesis Announces Non-Brokered Private Placement

Mon, 11 May 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million.This Offering is subject to...

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

Thu, 16 Apr 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada.Presentation Details:Date: Wednesday, April 22, 2026Time:...

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Mon, 02 Feb 2026 09:00:00 -0500

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University...

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Fri, 23 Jan 2026 09:00:00 -0500

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improvement San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients...

Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

Tue, 13 Jan 2026 09:00:00 -0500

San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that an abstract outlining preliminary results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in the EU has been...

Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Mon, 05 Jan 2026 09:00:00 -0500

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome Trial San Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United...

Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

Mon, 24 Nov 2025 09:00:00 -0500

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosing San Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of...

Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Tue, 04 Nov 2025 09:00:00 -0500

Trial achieved biological proof-of-concept, dose discovery and biomarker improvement San Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-based therapeutics for pediatric diseases, predominantly those involving mitochondrial dysfunction, today announced interim results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial...

Thiogenesis Announces Extension to Investor Relations Agreement

Fri, 03 Oct 2025 16:00:00 -0400

San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces the extension of its investor relations agreement with Triomphe Holdings Ltd., doing business as Capital Analytica (Consultant) for a further 3-month...

Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update

Thu, 11 Sep 2025 09:00:00 -0400

San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual General Meeting of Shareholders ("AGM") held on September 5, 2025, and provided a corporate update highlighting recent clinical and regulatory milestones.AGM ResultsShareholders re-elected...